MedTrace Logo

Association Between Autologous Transfusion and Recurrence-free Survival in Patients With HCC After Resection

NCT02654028 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 618

Last updated 2023-01-25

No results posted yet for this study

Summary

This prospective non-randomized controlled trial aims to determine whether autotransfusion of red blood cells salvaged before liver resection is associated with the recurrence-free survival in patients with hepatocellular carcinoma.

Conditions

Interventions

PROCEDURE

Autotransfusion

These group of patients will receive autotransfusion before liver resection.

OTHER

Control group

These group of patients will not receive autotransfusion before liver resection.

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Principal Investigators

  • Jian-Hong Zhong, MD · Guangxi Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-05
Primary Completion
2021-12-30
Completion
2021-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02654028 on ClinicalTrials.gov